Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure

Jiang-hua Zhong1, Xiao-pan Chen, Mei-ling Yun

  • 1Department of Cardiology, Affiliated Hospital of Hainan Medical College, Haikou, China.

Insights

Carvedilol treatment reduced transmural heterogeneity of ventricular repolarization in rabbits with congestive heart failure (CHF). This effect in CHF rabbits may stem from carvedilol's direct electrophysiological properties.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Congestive heart failure (CHF) is associated with altered ventricular repolarization.
  • Transmural heterogeneity of ventricular repolarization is a key factor in arrhythmogenesis.

Purpose of the Study:

  • To investigate the impact of carvedilol on ventricular repolarization heterogeneity in a rabbit model of CHF.
  • To determine if carvedilol's effects are linked to its electrophysiological properties or ventricular remodeling.

Main Methods:

  • Rabbits were induced with CHF and divided into control, CHF, and carvedilol-treated CHF groups.
  • Monophasic action potential duration (MAPD) was measured across three myocardial layers.
  • Ventricular fibrillation threshold (VFT) and ventricular remodeling were assessed.

Main Results:

  • CHF rabbits exhibited decreased blood pressure, cardiac output, and increased peripheral resistance.
  • CHF significantly increased transmural dispersion of repolarization (TDR) and prolonged MAPD, particularly in the midmyocardium.
  • Low-dose carvedilol treatment increased VFT and significantly reduced TDR in CHF rabbits, without affecting ventricular remodeling.

Conclusions:

  • CHF increases transmural heterogeneity of ventricular repolarization in rabbits.
  • Low-dose carvedilol effectively mitigates this heterogeneity in CHF.
  • Carvedilol's beneficial electrophysiological effects in CHF appear independent of ventricular remodeling.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...